test

Delmer Dee Raibourn III

@Avidity Partners Management Lp

Latest period2024 - Q3ReportedManaged Assets$1.96BTotal holdings81
Assets growth rate-16.7%Assets growth rate (2-Q avg)-20.41%Continuous growth in asset value0 quarters

Portfolio positions

This chart displays the top 10 holdings in Avidity Partners Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 81 positions.

Assets under management

The assets under management (AUM) of Avidity Partners Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.96B in assets, with a quarterly growth rate of -16.7% and a 2-quarter average growth rate of -20.41%. The portfolio is managed by Delmer Dee Raibourn III, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
GPCRStructure Therapeutics Inc
Recent Activity
Decreased -59.91%
0.97%
$18.912M
430,900 shares@ $43.89 avg price
NGNENeurogene Inc
Recent Activity
Decreased -41.57%
0.91%
$17.835M
425,041 shares@ $41.96 avg price
TERNTerns Pharmaceuticals Inc
Recent Activity
New Position
0.91%
$17.796M
2.134M shares@ $8.34 avg price
ASNDAscendis Pharma A S
Recent Activity
New Position
0.91%
$17.768M
119,000 shares@ $149.31 avg price
BNTXBiontech Se
Recent Activity
New Position
0.88%
$17.222M
145,000 shares@ $118.77 avg price
ITCIIntra-cellular Therapies Inc
Recent Activity
Decreased -41.75%
0.87%
$17.049M
233,000 shares@ $73.17 avg price
KROSKeros Therapeutics Inc
Recent Activity
Decreased -14.56%
0.87%
$17.026M
293,200 shares@ $58.07 avg price
DXCMDexcom Inc
Recent Activity
Decreased -7.33%
0.83%
$16.09M
240,000 shares@ $67.04 avg price
ORICOric Pharmaceuticals Inc
Recent Activity
New Position
0.76%
$14.833M
1.447M shares@ $10.26 avg price
NAMSNewamsterdam Pharma Company
Recent Activity
Increased 59.08%
0.76%
$14.769M
889,700 shares@ $16.6 avg price